The selective peroxisome proliferator–activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice

Fahrettin Haczeyni, Hans Wang, Vanessa Barn, Auvro R. Mridha, Matthew M. Yeh, W. Geoffrey Haigh, George N. Ioannou, Yun Jung Choi, Charles A. McWherter, Narcissus C.H. Teoh, Geoffrey C. Farrell^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review